Clicky

Hbm Holdings Ltd(2142)

Description: HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.


Keywords: Medicine Biopharmaceutical Immunology Solid Tumors Cancer Immunotherapy Antibody Monoclonal Antibody Multiple Myeloma Bispecific Monoclonal Antibody Breast And Gastric Cancers

Home Page: www.harbourbiomed.com

Tower A, 12th Floor
Shanghai, 200032
China
Phone: 86 21 5339 9123


Officers

Name Title
Dr. Jingsong Wang M.D., Ph.D. Founder, Chairman & CEO
Mr. Weihao Xu CFO, Chief Bus. Officer and Global Head of Bus. & Corp. Devel.
Dr. Frank Grosveld Founding Chief Scientific Officer & Member of Scientific Advisory Board
Mr. Bruce Zhang Head of Legal
Dr. Peter F. Moesta Ph.D. Member of Scientific Advisory Board & Chief CMC Advisor
Dr. George Liu Head of Early Devel. and Scientific Operations
Mr. Liu Lile Sr. VP, Head of Technology Platform & Head of Suzhou Operations
Dr. Yiping Rong Ph.D. Sr. VP, Head of Discovery & Exec. Director
Dr. Humphrey A. R. Gardner FCAP, M.D. Chief Medical Officer
Dr. Xiaolu Tao Sr. VP & Head of Translational Devel.

Exchange: HK

Country: HK : Hong Kong

Currency: Hong Kong Dollar (HK$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.0818
Price-to-Sales TTM: 49.6607
IPO Date:
Fiscal Year End: December
Full Time Employees: 396
Back to stocks